Registering a Homeopathic Medicine in Canada: What the DIN-HM Pathway Actually Requires

Most Canadian manufacturers who’ve navigated a Natural Product Number (NPN) application assume they understand the homeopathic medicine pathway too. The underlying framework is the same — the Natural Health Products Regulations (SOR/2003-196) — and the same Health Canada directorate handles both. But assume too much similarity and you’ll end up submitting the wrong evidence package, using the wrong labelling format, or applying for the wrong licence scope entirely.

Homeopathic medicines in Canada are issued a Drug Identification Number for Homeopathic Medicines (DIN-HM), not an NPN. That’s more than a cosmetic distinction. It reflects a fundamentally different evidentiary standard, different labelling obligations, and, in practice, a submission that requires very specific documentation that most regulatory teams haven’t built before. Knowing these differences before you finalize your formulation — not after — makes the difference between a smooth review and months of back-and-forth with the Natural Health Products Directorate (NHPD).

Here’s what you actually need to know.

What the DIN-HM Designation Actually Means

Under the NHPR, a “homeopathic medicine” is defined as a drug manufactured using a substance — or combination of substances — prepared in accordance with a pharmacopoeia recognized by Health Canada. The final product must be in a sufficiently dilute form that it presents no direct biological activity.

That dilution threshold is critical. It’s what separates a DIN-HM product from a conventional NHP — and from a drug requiring a full new drug submission under the Food and Drugs Act. Products where the medicinal ingredient retains measurable biological activity are assessed as NHPs or, at higher concentrations, as conventional drugs. Submitting a botanically-derived tincture at a 1:5 concentration as a DIN-HM product, for instance, will result in a deficiency notice or a reclassification recommendation. The NHPD review teams know what homeopathic dilution looks like, and they’ll flag anything that doesn’t fit.

The NHPR has been governing both NHPs and homeopathic medicines since 2004 — now over two decades of established practice. But the review standards for DIN-HM submissions have matured considerably in that time, and the expectations Health Canada communicates in its guidance documents are meaningfully more detailed than they were in the early years of the framework.

Building Your Evidence Package Around Pharmacopoeia References

Unlike NPN submissions, which can rely on Health Canada’s published NHP monographs to support claims and safety, DIN-HM applications must be grounded in recognized homeopathic pharmacopoeias. Health Canada’s list of accepted references includes the Homeopathic Pharmacopoeia of the United States (HPUS), the German Homeopathic Pharmacopoeia (HAB), the Homeopathic Pharmacopoeia International (HomInt), the homeopathic sections of the European Pharmacopoeia (Ph.Eur.), and the British Homeopathic Pharmacopoeia (BHomP), among others.

Each medicinal ingredient in your formulation — listed with its homeopathic name and potency notation (e.g., 6CH, 30CH, 12DH) — must appear in one of these recognized references. If an ingredient is only documented in a pharmacopoeia Health Canada doesn’t accept, you’re looking at a non-standard submission. Non-standard submissions require a significantly heavier evidence burden, including a more detailed safety and efficacy dossier. For most applicants, reformulating to pharmacopoeia-listed ingredients early in development is far more practical than defending a non-standard package during review.

Your non-medicinal ingredients — excipients, carriers, bases — are assessed using the same criteria as for NHPs. Ethanol, lactose globules, and aqueous vehicles are generally acceptable when used at appropriate levels and declared on the label. That said, if you’re using a non-standard vehicle or an excipient with limited prior authorization in Canada, build supporting documentation into your package early.

The claims you intend to make on the product are also constrained by the pharmacopoeia. Homeopathic medicines in Canada can make health claims, but only those consistent with the traditional homeopathic use documented in your reference source. Layering a contemporary health claim — “supports immune function” or “promotes cardiovascular health” — onto a DIN-HM product without pharmacopoeia support for that specific indication will trigger a deficiency request or a recommendation to reclassify the product.

Labelling Requirements That Are Non-Negotiable

Homeopathic medicine labelling in Canada generates more deficiency notices than almost any other aspect of the DIN-HM application, in our experience. And it’s almost always because applicants applied NHP labelling conventions directly without accounting for the DIN-HM-specific requirements.

The most fundamental point: the label must prominently display the bilingual designation “homeopathic medicine / médicament homéopathique.” This is not optional branding — it’s a regulated declaration that must appear in both official languages on the principal display panel. There’s no exemption for small formats or single-language markets. The DIN-HM number itself must appear on the approved label before you can sell the product in Canada.

Beyond that designation, eight mandatory elements must be present and accurate:

1. Product name
2. Medicinal ingredients listed by homeopathic name with potency notation
3. Non-medicinal ingredients
4. Net quantity or net amount
5. Recommended use or purpose, grounded in your pharmacopoeia evidence
6. Directions for use, including recommended dose and duration where applicable
7. Cautions, warnings, and contraindications appropriate to the product
8. Lot number and expiry date

A disconnect between your recommended use statement and your pharmacopoeia evidence is one of the most common reasons DIN-HM applications receive a deficiency notice. Health Canada reviewers cross-reference your label claim against your evidence package — if your indication goes even slightly beyond what the referenced pharmacopoeia supports, you’ll be asked to either narrow your claim or expand your evidence. Neither is a quick fix once a submission is in review.

Site Licensing and GMP — Don’t Assume You’re Already Covered

If your company already holds a Site Licence for NHP manufacturing or importation, confirm explicitly that your licence scope covers homeopathic medicines before submitting a DIN-HM product licence application. A Site Licence listing only “natural health product manufacturing” does not automatically extend to homeopathic medicine manufacturing, packaging, labelling, or importation. These are distinct activity categories, and Health Canada has taken compliance action against manufacturers who relied on a Site Licence that didn’t actually cover their homeopathic product line.

If your Site Licence needs to be amended to include homeopathic medicines, file that amendment first. Running both the Site Licence amendment and the product licence application concurrently is possible but adds complexity — a product licence cannot be finalized without a valid Site Licence in the correct scope.

GMP requirements under Part 3 of the NHPR apply fully to homeopathic medicines. Your manufacturing process, premises, equipment, sanitation, personnel qualifications, and quality control systems must meet the same standards as for conventional NHPs. Given the multiple dilution steps involved in homeopathic manufacturing, cross-contamination controls tend to get particular attention during inspections. Inspectors will look for evidence that potencies are clearly segregated between production runs and that your dilution records are traceable and complete.

Site Licences must be renewed annually. The renewal window opens 60 days before expiry — if you miss that window and your licence lapses, you’re technically operating without authorization during the gap. That can complicate a DIN-HM product licence application that’s already in progress and, in enforcement terms, isn’t something you want on your compliance record.

Common Reasons DIN-HM Submissions Stall

After working through a range of these submissions, a few patterns emerge reliably:

Potency notation errors. CH (Centesimal Hahnemannian) and DH (Decimal Hahnemannian) are not interchangeable on a label or in a submission. An error here isn’t a typo — it’s a factual inaccuracy about the composition of your product, and it will generate an immediate deficiency.

Mixing conventional and homeopathic claim language. Phrases like “clinically studied” or “scientifically formulated” don’t belong on a DIN-HM label. They imply a level of evidence that homeopathic submissions don’t provide and will draw either a deficiency request or a reclassification recommendation.

Incomplete pharmacopoeia citations. Referencing the HPUS or HAB by name isn’t sufficient. You need to identify the specific edition, the specific monograph, and the specific potency range that monograph supports. Health Canada reviewers check these citations, and an incomplete reference will slow your review.

Site Licence scope gaps. Confirm your Site Licence explicitly lists homeopathic medicines. If it doesn’t, amend it before you submit your product licence application.

Incorrect dosage form declaration. Globules, tablets, oral liquids, and topical preparations each carry specific labelling and GMP considerations under the NHPR. Declaring a dosage form incorrectly — or using a dosage form description borrowed from NHP conventions that doesn’t align with homeopathic standards — creates friction in the review process that’s avoidable with careful preparation.

A well-prepared DIN-HM submission should move through Health Canada’s review queue on a timeline comparable to a similar NPN application. But the preparation itself typically takes longer for teams without prior homeopathic regulatory experience, simply because the evidence architecture is unfamiliar territory. Starting the pharmacopoeia research early — before finalizing your formulation — is the single most effective step you can take to keep timelines manageable and deficiency notices to a minimum.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Supplement testing and label accuracy verification for North American markets — Qalitex Laboratories provides ISO 17025-accredited testing for manufacturers verifying ingredient identity, potency, and contaminant limits before submission.
• EU cosmetic and health product regulatory guidance for European market entry — Care Europe supports manufacturers with EU 1223/2009 compliance, REACH requirements, and CPSR documentation for brands expanding beyond Canada.